Stock Events

Stock Events

Sol-Gel Technologies 

$79.88
0
+$0+0% Wednesday 06:37

Statistics

Day High
80
Day Low
79.81
52W High
-
52W Low
-
Volume
24
Avg. Volume
-
Mkt Cap
222.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q3 2025
Q4 2025
Next
-2.13
-1.29
-0.45
0.39
Expected EPS
-1.84
Actual EPS
N/A

Financials

-91.7%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
23.08MRevenue
-21.16MNet Income

Analyst Ratings

$110.00Average Price Target
The highest estimate is 110.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SLGL.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Amneal Pharmaceuticals
AMRX
Mkt Cap3.4B
Amneal Pharmaceuticals, Inc. produces generic and specialty pharmaceutical products, including dermatological treatments, which compete with Sol-Gel's dermatology product line.
ANI Pharmaceuticals
ANIP
Mkt Cap2.1B
ANI Pharmaceuticals, Inc. develops, manufactures, and markets branded and generic prescription pharmaceuticals, in direct competition with Sol-Gel's pharmaceutical products.
Collegium Pharmaceutical
COLL
Mkt Cap1.13B
Collegium Pharmaceutical, Inc. is focused on developing and commercializing pain management and other products, competing in the same therapeutic areas as Sol-Gel.
Journey Medical
DERM
Mkt Cap213.64M
Dermira, Inc. focuses on advancing new therapies in dermatology, directly competing with Sol-Gel Technologies in the dermatological market.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, develops and markets pharmaceutical products for various therapeutic areas, including dermatology, competing with Sol-Gel's offerings.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. offers prescription medicines, vaccines, biologic therapies, and animal health products, including treatments in dermatology and acute pain, competing with Sol-Gel.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is involved in the discovery, development, manufacture, and sale of healthcare products, including those for dermatological conditions, competing with Sol-Gel.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries Limited specializes in generic and specialty medicines, including dermatology, directly competing with Sol-Gel's product range.

About

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Show more...
CEO
ISIN
IL0011417206

Listings

F
DE
4SG.F
XNAS
US
SLGL
BOATS
BOATS
SLGL.BOATS

0 Comments

Share your thoughts

FAQ

What is Sol-Gel Technologies stock price today?▼
The current price of SLGL.BOATS is $79.88 USD — it has increased by +0% in the past 24 hours. Watch Sol-Gel Technologies stock price performance more closely on the chart.
What is Sol-Gel Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sol-Gel Technologies stocks are traded under the ticker SLGL.BOATS.
What is Sol-Gel Technologies market cap?▼
Today Sol-Gel Technologies has the market capitalization of 222.55M
When is the next Sol-Gel Technologies earnings date?▼
Sol-Gel Technologies is going to release the next earnings report on May 08, 2026.
What were Sol-Gel Technologies earnings last quarter?▼
SLGL.BOATS earnings for the last quarter are 0.39 USD per share, whereas the estimation was 0.39 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Sol-Gel Technologies revenue for the last year?▼
Sol-Gel Technologies revenue for the last year amounts to 23.08M USD.
What is Sol-Gel Technologies net income for the last year?▼
SLGL.BOATS net income for the last year is -21.16M USD.
When did Sol-Gel Technologies complete a stock split?▼
The last stock split for Sol-Gel Technologies was on May 05, 2025 with a ratio of 1:10.